Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β-Reference-Cited by-同舟云学术

Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β

Published:2017-06-28 Issue:396 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hart Kevin M.¹^ORCID,Fabre Thomas²³^ORCID,Sciurba Joshua C.¹^ORCID,Gieseck Richard L.¹^ORCID,Borthwick Lee A.⁴,Vannella Kevin M.¹,Acciani Thomas H.¹^ORCID,de Queiroz Prado Rafael¹,Thompson Robert W.¹^ORCID,White Sandra¹^ORCID,Soucy Genevieve²⁵,Bilodeau Marc²⁶,Ramalingam Thirumalai R.¹,Arron Joseph R.⁷,Shoukry Naglaa H.²⁶^ORCID,Wynn Thomas A.¹^ORCID

Affiliation:

1. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, Canada.

3. Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada.

4. Tissue Fibrosis and Repair Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

5. Département de pathologie et biologie cellulaire, Université de Montréal, Montréal, Québec, Canada.

6. Département de médecine, Université de Montréal, Montréal, Québec, Canada.

7. Genentech Inc., South San Francisco, CA 94080, USA.

Abstract

Development of NASH fibrosis is accompanied by accumulation of hepatic eosinophils and driven by TGF-β and profibrotic type 2 inflammation.

Funder

NIH Office of the Director

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference55 articles.

1. Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

2. Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities

3. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008

4. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

5. Non-alcoholic fatty liver disease in 2016

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics;Livers;2024-09-13

2. The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects;Hepatology Communications;2024-09

3. The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease;Frontiers in Endocrinology;2024-08-08

4. Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease;Nature Reviews Immunology;2024-07-09

5. Effects of a Two-Year Lifestyle Intervention on Intrahepatic Fat Reduction and Renal Health: Mitigation of Inflammation and Oxidative Stress, a Randomized Trial;Antioxidants;2024-06-21